CDK2 and ovarian cancer: Additionally, the surprising degree of resistance of cells without 19q12 amplification to CCNE1 knockdown suggests that CDK2 inhibitor clinical trials should incorporate careful pre-selection of ovarian cancer patients and other tumor subtypes associated with Cyclin E1 over-expression, such as triple-negative and basal-like breast tumors [36].